Afuresertib (GSK21110183) is a reversible, ATP-competitive pan-Akt inhibitor that has entered clinical trials, both as monotherapy and combination with other agents, for solid tumors and MM [221,222,223]. The gene discussed is AKT1; the disease is Miyoshi myopathy.